Sugi Predict

Sugi Predict / Compounds / SCHEMBL940892

SCHEMBL940892

SCHEMBL940892

CN1C(=O)N(CC(=O)CBr)C(=O)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PLA2G7 Q13093 2/20 0.40
▸ KMT2A Q03164 1/20 0.36
▸ MMP2 P08253 12/20 0.34
▸ MMP1 P03956 11/20 0.34
▸ MMP9 P14780 9/20 0.34
▸ MMP13 P45452 7/20 0.34
▸ MMP3 P08254 7/20 0.34
▸ MMP8 P22894 5/20 0.34
▸ MMP7 P09237 2/20 0.32
▸ MMP14 P50281 2/20 0.32
▸ ADAM17 P78536 1/20 0.32
▸ NR1H2 P55055 1/20 0.30
▸ NR1H3 Q13133 1/20 0.30
▸ GRM2 Q14416 1/20 0.30
▸ FPR2 P25090 1/20 0.30
▸ RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7448180 0.84 PLA2G7 (0.42) PLA2G7KMT2AMMP2MMP1MMP9
SCHEMBL4756856 0.79 KMT2A (0.56) PLA2G7KMT2AMMP2MMP1MMP9
SCHEMBL14009878 0.79 PLA2G7 (0.42) PLA2G7KMT2AMMP2MMP1MMP9
SCHEMBL5036973 0.77 PLA2G7 (0.46) PLA2G7KMT2AMMP2MMP1MMP9
SCHEMBL7974805 0.76 PLA2G7 (0.38) PLA2G7KMT2AMMP2MMP1MMP9
SCHEMBL7500331 0.75 KMT2A (0.66) KMT2AFPR2
SCHEMBL6945464 0.75 PLA2G7 (0.49) PLA2G7MMP2MMP1MMP9MMP13
SCHEMBL7504403 0.73 PLA2G7 (0.49) PLA2G7KMT2AMMP2MMP1MMP9
SCHEMBL422413 0.71 PLA2G7 (0.49) PLA2G7KMT2AMMP2MMP1MMP9
SCHEMBL1593903 0.70 PLA2G7 (0.45) PLA2G7MMP2MMP1MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7625934-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2009-12-01 — — US disclosed
US-20080306065-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-12-11 — — US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 — — US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 — — US disclosed
EP-1370556-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2006-07-19 — — EP disclosed
EP-1676846-A2 Hydantoin derivatives as MMP inhibitors AstraZeneca AB (SE) 2006-07-05 — — EP disclosed
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 — — US disclosed
US-20040127528-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-01 — — US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 — — EP disclosed
EP-1370556-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 — — EP disclosed
EP-1001930-B1 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LAB (US) 2002-12-04 — — EP disclosed
WO-2002074767-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 — — WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 — — WO disclosed
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases DAVIDSEN STEVEN K (US) 2002-01-17 — — US disclosed
US-6294573-B1 FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION ABBOTT LABORATORIES 2001-09-25 — — US disclosed
US-6235786-B1 RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS ABBOTT LABORATORIES 2001-05-22 — — US disclosed
EP-1001930-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES Abbott Laboratories (US) 2000-05-24 — — EP disclosed
WO-1999006361-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LABORATORIES (US) 1999-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003853-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 PLA2G7 289/4885KMT2A 1563/4885MMP2 15/4885
US-20080306065-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 PLA2G7 289/4885KMT2A 1563/4885MMP2 15/4885
US-20080171882-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 PLA2G7 289/4885KMT2A 1563/4885MMP2 15/4885
US-20040127528-A1 Metalloproteinase inhibitors MMP9, MMP10, MMP3 PLA2G7 244/4885KMT2A 1715/4885MMP2 11/4885
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases MMP1, MMP9, MMP3 PLA2G7 267/4885KMT2A 2306/4885MMP2 4/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 PLA2G7 776/4885KMT2A 2278/4885MMP2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.